| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 8,620 | 6,041 | ||
| Prepaid expenses and other current assets | 2,877 | 1,950 | ||
| Total current assets | 11,497 | 7,991 | ||
| Property and equipment, net | 580 | 588 | ||
| Right of use assets - operating leases | 312 | 362 | ||
| Right of use assets - finance leases | 0 | 0 | ||
| Other long-term prepaid assets | 24 | - | ||
| Total assets | 12,413 | 8,941 | ||
| Accounts payable | 2,731 | 1,706 | ||
| Accrued expenses | 1,144 | 1,310 | ||
| Warrant liability | 1,676 | - | ||
| Convertible note, net | 2,888 | - | ||
| Other current liabilities | 350 | 545 | ||
| Total current liabilities | 8,789 | 3,561 | ||
| Warrant liability, non-current | 1,882 | - | ||
| Operating lease liabilities, net of current portion | 148 | 185 | ||
| Warrant liability | - | 3,549 | ||
| Total liabilities | 10,819 | 7,295 | ||
| Series a convertible preferred stock, 0.0001 par value, 5,000 shares authorized 965 and no shares issued and outstanding at september30, 2025 and december31, 2024, respectively liquidation preference of 5,000 and zero at september30, 2025 and december31, 2024, respectively | 4,940 | 4,940 | ||
| Common stock, 0.0001 par value, 40,000 shares authorized and 10,543 and 9,422 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 1 | 1 | ||
| Additional paid-in capital | 56,987 | 52,440 | ||
| Accumulated other comprehensive loss | -4 | - | ||
| Accumulated deficit | -60,164 | -55,579 | ||
| Total serina therapeutics, inc. stockholders equity | 1,760 | 1,802 | ||
| Noncontrolling interest | -166 | -156 | ||
| Total stockholders equity | 1,594 | 1,646 | ||
| Total liabilities and stockholders equity | 12,413 | 8,941 | ||
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)